跳至主要内容
临床试验/TCTR20200425004
TCTR20200425004已完成未知

Evaluation of peri-implant crevicular fluid biomarkers and marginal bone loss in platform-switched and non-platform-switched implants: a randomised prospective clinical study

istanbul university scientific research project0 个研究点目标入组 27 人开始时间: 2020年4月25日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
27

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
30 Years 至 70 Years(—)
性别
All

入选标准

  • an implant site without acute infection or bone defects; a bone crest ≥7 mm; a full-mouth plaque score (modified plaque index [mPI]) and full-mouth bleeding score (bleeding on probing [BOP]) ≤25%; ≤10 cigarettes per day if a smoker; and a peri-implant keratinised tissue width ≥2 mm.

排除标准

  • systemic medical conditions such as diabetes and any medication that could influence healing of soft or hard tissue.
  • full-mouth plaque score (modified plaque index [mPI]) and full-mouth bleeding score (bleeding on probing [BOP]) more than 25%; 10 and more cigarettes per day if a smoker; and a peri-implant keratinised tissue width less than 2 mm.

研究者

发起方
istanbul university scientific research project

相似试验